The SURMOUNT-5 trial (Aronne et al., NEJM 2025) showed that tirzepatide, a dual GIPGLP-1 receptor agonist, outperforms semaglutide in reducing weight and cardiometabolic risk in adults with obesity without diabetes
But, like other GLP-1 medications, you still need to pay close attention to whats on your plate to mitigate side effects, support your weight loss, and boost your overall well-being
Las redes sociales y los titulares ayudaron a instalar una narrativa que simplifica lo complejo: la inyeccin para adelgazar
If you are exploring peptide therapy online for the first time, understanding how telehealth evaluations work is valuable background knowledge
Tirzepatide for Obesity Tirzepatide is currently under investigation as a potential treatment for obesity within the SURMOUNT development program launched by Eli Lilly and Co [21]
Youll meet with your provider via phone or video